In this study, we report the identification and characterization of three FDA-approved compounds (DB16703, DB08512, and DB16047) with strong binding affinities and favorable interaction profiles across three critical AML targets—LSD1, BCL-2, and mutant IDH1 (R132H). This evidence concerns the gene KDM1A and acute myeloid leukemia.